Can-Fite BioPharma Ltd. (CANF)
- Previous Close
2.0200 - Open
2.1500 - Bid 2.0100 x 1400
- Ask 2.1900 x 1800
- Day's Range
2.0000 - 2.2000 - 52 Week Range
1.8100 - 3.3300 - Volume
132,465 - Avg. Volume
17,639 - Market Cap (intraday)
11.139M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0000 - Earnings Date May 30, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
www.canfite.comRecent News: CANF
Performance Overview: CANF
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CANF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CANF
Valuation Measures
Market Cap
10.92M
Enterprise Value
2.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.58
Price/Book (mrq)
1.61
Enterprise Value/Revenue
2.75
Enterprise Value/EBITDA
-0.25
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.15%
Return on Equity (ttm)
-142.49%
Revenue (ttm)
743k
Net Income Avi to Common (ttm)
-7.63M
Diluted EPS (ttm)
-3.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
8.92M
Total Debt/Equity (mrq)
0.64%
Levered Free Cash Flow (ttm)
-5.12M
Research Analysis: CANF
Company Insights: CANF
CANF does not have Company Insights